Kronos Bio, co-founded by Angela Koehler to tackle “undruggable” cancer targets, has launched a collaboration with Genentech. Genentech will leverage Kronos Bio’s drug discovery platform—including its small molecule microarray—to identify compounds that modify difficult-to-target transcription factors, with the aim of developing more effective treatments for cancer patients.